Prognosis analysis of palliative chemotherapy combined with radical local gastric surgery for advanced gastric cancer patients with single non-curable factor

Abstract There are limited studies on the treatment of patients with advanced gastric cancer with a single non-curable factor by palliative chemotherapy (PC) combined with local radical gastrectomy (LRG).In this study, our aim is to analyze the effectiveness and safety of palliative chemotherapy combined with local radical gastrectomy(PC-LRG)for patients with advanced gastric cancer with a single non-resectable factor. We retrospectively analyzed the patients with advanced gastric cancer with a single unresectable factor who received first-line chemotherapy in Fujian Provincial Hospital from January 2017 to June 2023. In total, 69 consecutive patients were enrolled into the PC(39 patients) and LRG-PC (30 patients) group. The primary research endpoint is the overall survival (OS) of patients in both groups, and the secondary research endpoint is the time of resistance to the first-line chemotherapy protocol.The OS of the PC-LGR group (20.0 VS 10.0 months, P<0.0001) and the time for changing the first-line chemotherapy plan (7.5 VS 3.2 cycles, p<0.05) were significantly better. There was statistical significance between the average total number of chemotherapy cycles of the two groups (8.7 VS 6.1, p<0.05). The incidence of grade III or higher adverse reactions to chemotherapy in the PC group (12.8% VS 33.3%, p=0.41) was better than that in the PC-LGR group.For patients with advanced gastric cancer who have a single non-reversible factor, PC-LGR may reduce tumor burden, improve tolerance to chemotherapy drugs, and prolong the OS of patients.